Skip to main content

Mircera and Alcohol/Food Interactions

There is 1 alcohol/food/lifestyle interaction with Mircera (epoetin beta-methoxy polyethylene glycol).


Epoetin Beta-Methoxy Polyethylene Glycol High Blood Pressure (Hypertension)

Major Potential Hazard, Moderate plausibility

erythropoiesis-stimulating agents - hypertension

The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension. These agents may cause blood pressure to rise. Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents. Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment. Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing. It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.


  1. Bennett WM (1991) "Side effects of erythropoietin therapy." Am J Kidney Dis, 18, p. 84-6
  2. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. (1989) "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med, 111, p. 992-1000
  3. Raine AE (1988) "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet, 1, p. 97-100
  4. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW (1990) "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens, 3, p. 947-55
  5. (2002) "Product Information. Epogen (epoetin alfa)." Amgen
  6. (2002) "Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc
  7. Singbartl G (1994) "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig, 72, s36-43
  8. (2001) "Product Information. Aranesp (darbepoetin alfa)." Amgen
  9. (2007) "Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT
View all 9 references

Mircera drug interactions

There are 23 drug interactions with Mircera (epoetin beta-methoxy polyethylene glycol).

Mircera disease interactions

There are 4 disease interactions with Mircera (epoetin beta-methoxy polyethylene glycol) which include:

Report options

QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.